Fig. 7

PERP and/or GNAS2 and/or GNA13 and/or ITB1 and/or RAB10 are upregulated in the blood extracellular vesicles of patients with ErbB2-positive metastatic breast cancer that benefited from trastuzumab-based therapies but not in those derived from patients that failed these treatments. Blood was collected from the indicated patients on the indicated days during trastuzumab (TZ)-based therapies. The day of the first blood collection was designated as “day 0.” Normally, blood was collected 1 day prior to the therapy. The extracellular vesicles were isolated from patients’ blood by ultracentrifugation and tested for the levels of the indicated proteins by western blotting. Extracellular vesicle markers Flotillin-1 and TSG101 are loading controls. Patients’ metastatic disease status (shown above each blot) was assessed based on the comparison of their CT scans performed as closely as possible to the dates of the first and the last blood collection. Data for patients showing partial response or stable disease (a) or those with progressive disease (b) are shown